Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors by Mario Occhipinti, Marta Brambilla, Giulia Galli, Sara Manglaviti, Maristella Giammaruco, Arsela Prelaj, Roberto Ferrara, Alessandro De Toma, Claudia Proto, Teresa Beninato, Emma Zattarin, Giuseppe Lo Russo, Alain Jonathan Gelibter, Maurizio Simmaco, Robert Preissner, Marina Chiara Garassino, Filippo De Braud, Paolo Marchetti

“…We enrolled patients with Stage IV aNSCLC already treated with or candidates to receive EGFR-TKIs, in any line; ECOG PS 0–2; taking at least one concomitant drug. Cancer treatments, concomitant drugs, and clinical and laboratory data were collected and inserted in Drug-PIN^®. (3) Results. …”
Get full text

Epidemiology of Breast Cancer in Mexican Women with Obesity as a Risk Factor by Shaila Cejudo-Arteaga, Miguel Ángel Guerrero-Ramos, Roberto Kuri-Exome, Erika Martínez-Cordero, Felipe Farias-Serratos, María Maldonado-Vega

“…Mexican women studied and treated for breast cancer have an BMI of 29 from diagnosis and at the end of their cancer treatments. The average age was 52 ± 12 years, 54% in women older than 55 years. …”
Get full text

Methoxylated Cinnamic Esters with Antiproliferative and Antimetastatic Effects on Human Lung Adenocarcinoma Cells by João Graciano Sampaio, Carolina Girotto Pressete, Adilson Vidal Costa, Felipe Terra Martins, Graziela Domingues de Almeida Lima, Marisa Ionta, Róbson Ricardo Teixeira

“…Despite improvements in therapeutic approaches, cancer treatments are not completely effective. Thus, new drug candidates are continuously sought. …”
Get full text

Improving Tirapazamine (TPZ) to Target and Eradicate Hypoxia Tumors by Gold Nanoparticle Carriers by Giimel Ajnai, Chun-Chia Cheng, Tzu-Chun Kan, Jeng-Wei Lu, Sri Rahayu, Amy Chiu, Jungshan Chang

“…Tumor hypoxia is a hallmark of solid tumors and emerged as the therapeutic target for cancer treatments, such as a prodrug Tirapazamine (TPZ) activated in hypoxia. …”
Get full text

Ubiquitin Conjugating Enzyme E2 H (UBE2H) Is Linked to Poor Outcomes and Metastasis in Lung Adenocarcinoma by Meng-Chi Yen, Kuan-Li Wu, Yu-Wei Liu, Yung-Yun Chang, Chao-Yuan Chang, Jen-Yu Hung, Ying-Ming Tsai, Ya-Ling Hsu

“…Although novel lung cancer treatments have been developed for metastatic LUAD, not all patients are fit to receive these treatments. …”
Get full text

Sexual functioning in patients with cancer by A. Guermazi, S. Hentati, R. Masmoudi, F. Guermazi, I. Baati, I. Feki, J. Masmoudi

“… Introduction Sexuality is a growing field in the context of the management of chronic diseases and cancer in particular. Cancer treatments and the traumatic nature of the cancer experience frequently elicit considerable sexual difficulties. …”
Get full text

Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic by David J. H. Bian, Siham Sabri, Bassam S. Abdulkarim

“…The immunological and inflammatory pathophysiological similarities between lung cancer and COVID-19-related ARDS might explain the predisposition of cancer patients to severe COVID-19, while multiple risk factors in lung cancer patients have been associated with worse COVID-19 outcomes, including smoking status, older age, etc. Recent cancer treatments have also been urgently evaluated during the pandemic as potential risk factors for severe COVID-19, with conflicting findings regarding systemic chemotherapy and radiation therapy, while other therapies were not associated with altered outcomes. …”
Get full text

Natural products and mitochondrial allies in colorectal cancer therapy by Feng Wei, Qing Nian, Maoyuan Zhao, Yueqiang Wen, Yi Yang, Jundong Wang, Zhelin He, Xiaoyan Chen, Xiang Yin, Jian Wang, Xiao Ma, Yu Chen, Peimin Feng, Jinhao Zeng

“…Colorectal cancer (CRC) is a globally prevalent malignancy with a high potential for metastasis. Existing cancer treatments have limitations, including drug resistance and adverse effects. …”
Get full text

Dendritic Glycerol-Cholesterol Amphiphiles as Drug Delivery Systems: A Comparison between Monomeric and Polymeric Structures by Jocelyn Fernanda Romero, Svenja Herziger, Mariam Cherri, Mathias Dimde, Katharina Achazi, Ehsan Mohammadifar, Rainer Haag

“…The application of micelles as drug delivery systems has gained a great deal of attention as a means to overcome the current several drawbacks present in conventional cancer treatments. In this work, we highlight the comparison of polymeric and monomeric amphiphilic systems with a similar hydrophilic–lipophilic balance (HLB) in terms of their biocompatibility, aggregation behavior in aqueous solution, and potential in solubilizing hydrophobic compounds. …”
Get full text

Palliative tumor surgery for incurable head and neck cancer: indications and outcomes: A retrospective case review by Young Sang Cho, Eunkyu Lee, Hokyung Jin, Dongryul Oh, Han-Sin Jeong

“…Of note, further chemotherapy or other additional cancer treatments was possible in 66.7% of patients with PTS (P=0.002). …”
Get full text

MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and pre... by Andrew Hall, Sarah Brown, Sadie Roberts, Martin Kaiser, Kevin Boyd, Jessica Kendall, Holger W Auner, Mamta Garg

“…The selective nuclear export inhibitor, selinexor, has been relatively well tolerated in previous clinical trials and offers promise when used in combination with a wide range of other anti-cancer treatments. Here, we investigate if the addition of selinexor can improve responses to cyclophosphamide plus prednisolone without adding prohibitive toxicity.Methods and analysis MUKtwelve is a UK-based, randomised, controlled, open, parallel group, multicentre phase II trial designed to evaluate clinical efficacy of selinexor in combination with cyclophosphamide and prednisolone (SCP) in patients with relapsed or refractory multiple myeloma. …”
Get full text

Molecular Imaging of Brain Tumors and Drug Delivery Using CEST MRI: Promises and Challenges by Jianpan Huang, Zilin Chen, Se-Weon Park, Joseph H. C. Lai, Kannie W. Y. Chan

“…In this review, we will discuss the promises of CEST MRI in the identification of tumors, tumor grading, detecting molecular alterations related to isocitrate dehydrogenase (IDH) and O-6-methylguanine-DNA methyltransferase (MGMT), assessment of treatment effects, and using multiple contrasts of CEST to develop theranostic approaches for cancer treatments. Promising applications include (i) using the CEST contrast of amide protons of proteins/peptides to detect brain tumors, such as glioblastoma multiforme (GBM) and low-grade gliomas; (ii) using multiple CEST contrasts for tumor stratification, and (iii) evaluation of the efficacy of drug delivery without the need of metallic or radioactive labels. …”
Get full text

Population-level and individual-level explainers for propensity score matching in observational studies by Debashis Ghosh, Arya Amini, Bernard L. Jones, Sana D. Karam

“…Machine learning methods can help to identify how the study population differs from the unmatched subpopulation.BackgroundThere has been widespread use of propensity scores in evaluating the effect of cancer treatments on survival, particularly in administrative databases and cancer registries. …”
Get full text

An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study by Alessandro Passardi, Patrizia Serra, Caterina Donati, Federica Fiori, Sabrina Prati, Roberto Vespignani, Gabriele Taglioni, Patrizia Farfaneti Ghetti, Giovanni Martinelli, Oriana Nanni, Mattia Altini, Giovanni Luca Frassineti, Martina Vittoria Minguzzi

“…Some potential interactions between nonconventional medications and cancer treatments were reported. ConclusionsIn the PROF-1 (Progetto di Rete in Oncologia con le Farmacie di comunità della Romagna) study, an alliance was created between our cancer center and CPs to improve medication reconciliation, and a new integrated IT platform was validated. …”
Get full text

Multicentric, observational, longitudinal study for the evaluation of nutritional management implications in newly diagnosed Italian cancer patients: the Italian Registry of Malnut... by Paolo Pedrazzoli, Francesco De Lorenzo, Elisabetta Iannelli, Cristina Bosetti, Valentina Da Prat, Riccardo Caccialanza, Emanuele Cereda, Fortes Cristina, Alessandra Ferrari, Francesco Serra, Amanda Casirati, Sara Masi, Silvia Crotti, Lorenzo Perrone, Claudia Santucci, Caccialanza Riccardo, Cannizzaro Renato, Casalone Valentina, Cici Rosalisa, De Lorenzo Francesco, De Pergola Giovanni, Di Lauro Teresa, Gori Stefania, Ibrahim Toni, Longhi Alessandra, Mele Maria Cristina, Mele Roberto, Montemurro Filippo, Nardi Maria Teresa, Pedrazzoli Paolo, Pezzuolo Debora, Pinto Carmine, Pignata Sandro, Pozzo Carmelo, Sanchez Mete Lupe, Serra Patrizia, Sukkar Samir Guseppe, Tonello Marco, Zagonel Vittorina

“…Background Malnutrition is a frequent problem in oncology and is associated with reduced response to cancer treatments, increased drug-related toxicity, higher rates of clinical complications, reduced quality of life (QoL) and worse prognosis. …”
Get full text

Oncologists’ perceptions of tumor genomic profiling and barriers to communicating secondary hereditary risks to African American cancer patients by Michael J. Hall, Paul A. D’Avanzo, Yana Chertock, Patrick J. A. Kelly, Jesse Brajuha, Katie Singley, Caseem C. Luck, Sarah B. Bass

“…Abstract Background Tumor genomic profiling (TGP) identifies targets for precision cancer treatments, but also secondary hereditary risks. …”
Get full text

Butyrate dictates ferroptosis sensitivity through FFAR2-mTOR signaling by GuoYan Wang, SenLin Qin, Lei Chen, HuiJun Geng, YiNing Zheng, Chao Xia, JunHu Yao, Lu Deng

“…Altogether, in vivo results suggest that NaB treatment is correlated to the mTOR-dependent ferroptosis and consequent tumor growth through xenografts and colitis-associated colorectal tumorigenesis, implicating the potential clinical applications of NaB for future colorectal cancer treatments. Based on all these findings, we have proposed a regulatory mechanism via which butyrate inhibits the mTOR pathway to control ferroptosis and consequent tumorigenesis.…”
Get full text

Study of Protective Effects of Calendula Officinalis L. Hydrethanolic Extract on Blood Parameters in Wistar Rats Treated With Cyclophosphamide by Naser Mirazi, Aida Shahabi Baher, Zahra Izadi, Alireza Nourian, Samaneh Safari

“…Cyclophosphamid is a drug for malignant cancers treatment with subversion effects on blood hemopoetic bone marrow. …”
Get full text

One-Pot Synthesis and Evaluation of Antioxidative Stress and Anticancer Properties of an Active Chromone Derivative by Chirattikan Maicheen, Chokchaloemwat Churnthammakarn, Nichapat Pongsroypech, Thitiphong Khamkhenshorngphanuch, Jiraporn Ungwitayatorn, Kanin Rangsangthong, Rathapon Asasutjarit, Sewan Theeramunkong

“…A chromone scaffold possesses effective chemoprotective and antioxidant properties, making it a promising candidate for antioxidant and future cancer treatments.…”
Get full text

Expected Cost Savings From Low-Dose Computed Tomography Scan Screening for Lung Cancer in Alberta, Canada by Nguyen Xuan Thanh, MD, PhD, Truong-Minh Pham, MD, PhD, Arianna Waye, PhD, Alain Tremblay, MDCM, Huiming Yang, MD, Michelle L. Dean, BSc, Tracy Wasylak, MSc, Randeep Sangha, MD, Douglas Stewart, MD

“…Using patient-level data, HSU costs by stage of disease were estimated for patients with LC, including inpatient, outpatient, and physician services, and costs for prescription drugs and cancer treatments. Results: Of 101,000 people aged 55 to 74 years eligible for screening, an estimated 88,476 scans would be performed in Alberta in 3 years. …”
Get full text